These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35875538)

  • 1. Humanization of Yeasts for Glycan-Type End-Products.
    Li X; Shen J; Chen X; Chen L; Wan S; Qiu X; Chen K; Chen C; Tan H
    Front Microbiol; 2022; 13():930658. PubMed ID: 35875538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of N-/O-glycans assembled on proteins in yeasts.
    Thak EJ; Kim J; Lee DJ; Kim JY; Kang HA
    J Microbiol; 2018 Jan; 56(1):11-23. PubMed ID: 29299842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Yarrowia lipolytica to produce glycoproteins homogeneously modified with the universal Man3GlcNAc2 N-glycan core.
    De Pourcq K; Tiels P; Van Hecke A; Geysens S; Vervecken W; Callewaert N
    PLoS One; 2012; 7(6):e39976. PubMed ID: 22768188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering yeast for producing human glycoproteins: where are we now?
    Laukens B; De Visscher C; Callewaert N
    Future Microbiol; 2015; 10(1):21-34. PubMed ID: 25598335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in Yeast Glycosylation Engineering.
    Hamilton SR; Zha D
    Methods Mol Biol; 2015; 1321():73-90. PubMed ID: 26082216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The humanization of N-glycosylation pathways in yeast.
    Wildt S; Gerngross TU
    Nat Rev Microbiol; 2005 Feb; 3(2):119-28. PubMed ID: 15685223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering the yeast Yarrowia lipolytica for the production of therapeutic proteins homogeneously glycosylated with Man₈GlcNAc₂ and Man₅GlcNAc₂.
    De Pourcq K; Vervecken W; Dewerte I; Valevska A; Van Hecke A; Callewaert N
    Microb Cell Fact; 2012 May; 11():53. PubMed ID: 22548968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of galactosylated complex-type N-glycans in glycoengineered Saccharomyces cerevisiae.
    Piirainen MA; Salminen H; Frey AD
    Appl Microbiol Biotechnol; 2022 Jan; 106(1):301-315. PubMed ID: 34910238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomedical applications of yeasts - a patent view, part two: era of humanized yeasts and expanded applications.
    Roohvand F; Ehsani P; Abdollahpour-Alitappeh M; Shokri M; Kossari N
    Expert Opin Ther Pat; 2020 Aug; 30(8):609-631. PubMed ID: 32529867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual approach for improving homogeneity of a human-type N-glycan structure in Saccharomyces cerevisiae.
    Piirainen MA; Boer H; de Ruijter JC; Frey AD
    Glycoconj J; 2016 Apr; 33(2):189-99. PubMed ID: 26983412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering of Yeast Glycoprotein Expression.
    De Wachter C; Van Landuyt L; Callewaert N
    Adv Biochem Eng Biotechnol; 2021; 175():93-135. PubMed ID: 30397726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi.
    Gerngross TU
    Nat Biotechnol; 2004 Nov; 22(11):1409-14. PubMed ID: 15529166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycans.
    Hollister J; Grabenhorst E; Nimtz M; Conradt H; Jarvis DL
    Biochemistry; 2002 Dec; 41(50):15093-104. PubMed ID: 12475259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in systems and synthetic biology approaches for developing novel cell-factories in non-conventional yeasts.
    Patra P; Das M; Kundu P; Ghosh A
    Biotechnol Adv; 2021; 47():107695. PubMed ID: 33465474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoengineering of Aspergillus nidulans to produce precursors for humanized N-glycan structures.
    Anyaogu DC; Hansen AH; Hoof JB; Majewska NI; Contesini FJ; Paul JT; Nielsen KF; Hobley TJ; Yang S; Zhang H; Betenbaugh M; Mortensen UH
    Metab Eng; 2021 Sep; 67():153-163. PubMed ID: 34174425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up.
    Madhavan A; Arun KB; Sindhu R; Krishnamoorthy J; Reshmy R; Sirohi R; Pugazhendi A; Awasthi MK; Szakacs G; Binod P
    Microb Cell Fact; 2021 Jun; 20(1):124. PubMed ID: 34193127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced expression of heterologous proteins in yeast cells via the modification of N-glycosylation sites.
    Han M; Yu X
    Bioengineered; 2015; 6(2):115-8. PubMed ID: 25671496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycan engineering and production of 'humanized' glycoprotein in yeast cells.
    Chiba Y; Akeboshi H
    Biol Pharm Bull; 2009 May; 32(5):786-95. PubMed ID: 19420743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Glycoengineering on the Endoplasmic Reticulum Quality Control System in Yeasts.
    Piirainen MA; Frey AD
    Front Mol Biosci; 2022; 9():910709. PubMed ID: 35720120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. POMGNT1 Is Glycosylated by Mucin-Type O-Glycans.
    Xin X; Akasaka-Manya K; Manya H; Furukawa J; Kuwahara N; Okada K; Tsumoto H; Higashi N; Kato R; Shinohara Y; Irimura T; Endo T
    Biol Pharm Bull; 2015; 38(9):1389-94. PubMed ID: 26328495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.